Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury

Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury Jiaren Sun 1 , † * , Batbayar Tumurbaatar 1 , † , Junhui Jia 1 , Hong Diao 1 , Francis Bodola 1 , Stanley M. Lemon 1 , Wendell Tang 2 , David G. Bowen 3 , Geoffrey W. McCaughan 3 , Patrick Bertolino 3 , and Teh-Sheng Chan 1 1 Departments of Microbiology and Immunology 2 Pathology, Hepatitis Research Center, Sealy Center for Vaccine Development and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas 77555-1019 3 AW Morrow Gastroenterology and Liver Centre, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, Australia ABSTRACT Hepatitis C virus (HCV) infection is a major global health problem. Hepatic expression of immune costimulatory signaling molecules (e.g., B7) is known to be associated with ongoing liver injury in hepatitis C patients. However, due to the general lack of viral culture systems and adequate animal models, the function of these molecules in disease pathogenesis is poorly understood. To investigate the role of CD86 in HCV-related liver injury, we developed two transgenic mouse lineages with inducible expression of HCV structural proteins and constitutive expression of the costimulatory molecule CD86/B7.2 in the liver. Using a hydrodynamic-based, nonviral delivery protocol, we induced HCV transgene expression in the livers of HCV and CD86 single- and double-transgenic mice. We found that hepatic CD86 expression resulted in increased activation of and cytokine production (e.g., interleukin-2 and gamma interferon) by CD4 + T cells and that the retention of these cells was associated with more pronounced necroinflammatory lesions in the liver. Taken together, these data suggest that augmented, parenchymal antigen presentation conferred by hepatocyte CD86 expression alters homeostasis and effector functions of CD4 + T cells and contributes to liver injury. This study provides an additional rationale for exploring immunomodulation-based therapies that could reduce disease progression in individuals with chronic HCV infection. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Virology American Society For Microbiology

Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury

Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury

Journal of Virology , Volume 79 (16): 10730 – Aug 15, 2005

Abstract

Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury Jiaren Sun 1 , † * , Batbayar Tumurbaatar 1 , † , Junhui Jia 1 , Hong Diao 1 , Francis Bodola 1 , Stanley M. Lemon 1 , Wendell Tang 2 , David G. Bowen 3 , Geoffrey W. McCaughan 3 , Patrick Bertolino 3 , and Teh-Sheng Chan 1 1 Departments of Microbiology and Immunology 2 Pathology, Hepatitis Research Center, Sealy Center for Vaccine Development and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas 77555-1019 3 AW Morrow Gastroenterology and Liver Centre, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, Australia ABSTRACT Hepatitis C virus (HCV) infection is a major global health problem. Hepatic expression of immune costimulatory signaling molecules (e.g., B7) is known to be associated with ongoing liver injury in hepatitis C patients. However, due to the general lack of viral culture systems and adequate animal models, the function of these molecules in disease pathogenesis is poorly understood. To investigate the role of CD86 in HCV-related liver injury, we developed two transgenic mouse lineages with inducible expression of HCV structural proteins and constitutive expression of the costimulatory molecule CD86/B7.2 in the liver. Using a hydrodynamic-based, nonviral delivery protocol, we induced HCV transgene expression in the livers of HCV and CD86 single- and double-transgenic mice. We found that hepatic CD86 expression resulted in increased activation of and cytokine production (e.g., interleukin-2 and gamma interferon) by CD4 + T cells and that the retention of these cells was associated with more pronounced necroinflammatory lesions in the liver. Taken together, these data suggest that augmented, parenchymal antigen presentation conferred by hepatocyte CD86 expression alters homeostasis and effector functions of CD4 + T cells and contributes to liver injury. This study provides an additional rationale for exploring immunomodulation-based therapies that could reduce disease progression in individuals with chronic HCV infection.

Loading next page...
 
/lp/american-society-for-microbiology/parenchymal-expression-of-cd86-b7-2-contributes-to-hepatitis-c-virus-fV0wMGo3OI

References (70)

Publisher
American Society For Microbiology
Copyright
Copyright © 2005 by the American society for Microbiology.
ISSN
0022-538X
eISSN
1098-5514
DOI
10.1128/JVI.79.16.10730-10739.2005
pmid
16051865
Publisher site
See Article on Publisher Site

Abstract

Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury Jiaren Sun 1 , † * , Batbayar Tumurbaatar 1 , † , Junhui Jia 1 , Hong Diao 1 , Francis Bodola 1 , Stanley M. Lemon 1 , Wendell Tang 2 , David G. Bowen 3 , Geoffrey W. McCaughan 3 , Patrick Bertolino 3 , and Teh-Sheng Chan 1 1 Departments of Microbiology and Immunology 2 Pathology, Hepatitis Research Center, Sealy Center for Vaccine Development and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas 77555-1019 3 AW Morrow Gastroenterology and Liver Centre, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, Australia ABSTRACT Hepatitis C virus (HCV) infection is a major global health problem. Hepatic expression of immune costimulatory signaling molecules (e.g., B7) is known to be associated with ongoing liver injury in hepatitis C patients. However, due to the general lack of viral culture systems and adequate animal models, the function of these molecules in disease pathogenesis is poorly understood. To investigate the role of CD86 in HCV-related liver injury, we developed two transgenic mouse lineages with inducible expression of HCV structural proteins and constitutive expression of the costimulatory molecule CD86/B7.2 in the liver. Using a hydrodynamic-based, nonviral delivery protocol, we induced HCV transgene expression in the livers of HCV and CD86 single- and double-transgenic mice. We found that hepatic CD86 expression resulted in increased activation of and cytokine production (e.g., interleukin-2 and gamma interferon) by CD4 + T cells and that the retention of these cells was associated with more pronounced necroinflammatory lesions in the liver. Taken together, these data suggest that augmented, parenchymal antigen presentation conferred by hepatocyte CD86 expression alters homeostasis and effector functions of CD4 + T cells and contributes to liver injury. This study provides an additional rationale for exploring immunomodulation-based therapies that could reduce disease progression in individuals with chronic HCV infection.

Journal

Journal of VirologyAmerican Society For Microbiology

Published: Aug 15, 2005

There are no references for this article.